docRecent Research: Respiratory Syncytial Virus Treatment Market Will Surpass $2.3 Billion by 2024
download 
Report Transcription
Recent Research: Respiratory Syncytial Virus Treatment Market Will Surpass $2.3 Billion by 2024 According to a leading research and consulting firm, The Global Respiratory Syncytial Virus (RSV) treatment market will expand to unprecedented levels over the next decade, rising from approximately $640 million in 2014 to over $2.3 billion by 2024, representing an impressive Compound Annual Growth Rate (CAGR) of 29.9%. This report provides analysis of the Respiratory Syncytial Virus (RSV) treatment space across the seven Major Markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, including annualized market data from 2014 and forecast to 2024. It discusses current treatment options, unmet needs and opportunities, and the drivers and barriers affecting RSV product sales in the 7MM. Browse Detailed Toc, Tables, Figures, Charts and Companies Mentioned in Respiratory Syncytial Virus Treatment Market Research Report athttp://www.absolutereports.com/opportunityanalyzer-respiratory-syncytial-virus-rsv-opportunityanalysis-and-forecasts-to-2024-10112595 According to this latest report, this robust growth, which will occur across the seven Major Markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, will be driven by multiple new product launches in the currently sparse RSV arena. The director of a leading research firm states that, “Synagis (palivizumab) is the only licensed product indicated for the prevention of RSV in infants at a high risk of severe infection, and there are no prophylactic agents approved for adults”. Ask for Discount on Respiratory Syncytial Virus Treatment Market Research Report at – http://www.absolutereports.com/enquiry/request-discount/10112595 The director further explains: “Despite Synagis being effective in many patients, its short half-life and prohibitively high cost limit its utility. The anticipated launches of novel prophylactic monoclonal antibodies (mAbs) led by MedImmune’s MEDI8897 and Regeneron’s REGN2222, have provided hope for more cost-effective alternatives to Synagis. It is expected that these pipeline agents will be important players in the RSV space across the 7MM by 2024”. In addition, the anticipated licensure of the first adult vaccine to offer protection against RSV, Novavax’s RSV-F Vaccine, will also stimulate rapid growth in a previously untapped segment of the RSV marketplace, with elderly patients, especially those living in nursing homes. +1 408 520 9750 www.absolutereports.com Request sample PDF of this report at - http://www.absolutereports.com/enquiry/requestsample/10112595 These new products have come at a time when RSV presents a growing socioeconomic and public health burden. New game-changing agents will be enthusiastically welcomed, particularly as healthcare stakeholders are becoming increasingly open to novel interventions that may provide indirect costsavings by shortening, or even outright preventing, hospital stays. Despite the RSV treatment market’s promising prospects, there will be formidable logistical and financial hurdles to overcome in order to successfully assimilate novel RSV vaccines into existing immunization program infrastructure. However, such barriers will not hinder exciting market growth to 2024. About Absolute Report: Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters. Contact– Mr. Ameya Pingaley Absolute Reports +1-408 520 9750 Email – [email protected] Website: www.absolutereports.com +1 408 520 9750 www.absolutereports.com
Similar documents
Medtronic plc, Bioventus LLC and Depuy Companies Dominate the UK Orthobiologics Market Report
The orthobiologics market in the UK is expected to be driven by patient demographics, the development of novel product designs, increasing patient awareness, increasing participation in sports related activities, and a rising incidence of road accidents. The data in the report is derived from dynamic market forecast models.
France Orthopedic Prosthetics Procedure report to 2021, Market Shares, Research Report, Industry Analysis, Forecast Opportunity
prosthesis is a functional replacement for an amputated or congenitally malformed or missing limb. Prosthetists are responsible for the prescription, design and management of a prosthetic device. In most cases, the prosthetist begins by taking a plaster cast of the patient's affected limb. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market segments - Lower Extremity Prosthetics and Upper Extremity Prosthetics.
Latest Report: Glioblastoma Treatment Market Will Expand Fivefold to $3.3 Billion at a CAGR of 17.4% by 2024
The glioblastoma treatment market will increase fivefold from $659 million in 2014 to $3.3 billion by 2024, representing a rapid Compound Annual Growth Rate (CAGR) of 17.4% according to a leading research and consulting firm. Of the 7MM, Japan will see the most impressive relative growth, with sales expanding from $47 million in 2014 to $268 million in 2024, representing a CAGR of 19.7%.
Latest Research Report on Medical Equipment Monthly Deals Analysis: JANUARY 2016 - M&A and Investment Trends
Medical Equipment Monthly Deals Analysis: JANUARY 2016 report provides detailed information on M&As, equity/debt offerings, private equity, venture financing and partnership transactions registered in the medical equipment industry in January 2016.
AmVac AG Strong Team and Renowned Advisors INVESTMENT HIGHLIGHTS Portfolio with exceptional potential
Hepatitis B Virus (HBV) Therapeutics Market to Expand at a modest Compound Annual Growth Rate (CAGR) of 2.4% Up to 2024
The global hepatitis B market, which is set to experience limited growth from $2.4 billion in 2014 to $3 billion by 2024, is being stymied by the persistence of low diagnosis and treatment rates, according to research. Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains a serious global health concern, with estimated over 350 million people worldwide currently living with this condition.
Latest Research: US Will Remain Hernia Repair Market Leader by 2021
The overall US hernia repair market is expected to rise to approximately $1.2 billion by 2021, at a moderate Compound Annual Growth Rate (CAGR) of 4%. It was valued at approximately $875 million in 2014. The US has a higher adoption of expensive meshes in general, and procedure volume will go up by 1% annually. For example, the majority of umbilical hernia repairs are performed with composite meshes, which contribute to a higher market valuation.
Gaucher Disease (GD) - Market Insights, Epidemiology and Market Forecasts, 2024
The Report,” Gaucher Disease - Epidemiology Forecast to 2024" market research providing an overview of the risk factors and global trends of GD in the 7MM US, France, Germany, Italy, Spain, UK, and Israel. It includes a 10-year epidemiology forecast for the total prevalent cases of Type 1, 2, and 3 GD, segmented by age and sex in these markets. GD epidemiology report is written and developed by Masters- and PhD-level epidemiologists. The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Diagnosed Prevalent Cases of Fabry Disease in The 7MM Will Rise at an AGR of 7.71% By 2024
The report,” Fabry Disease - Epidemiology Forecast to 2024 “provides an overview of the risk factors, comorbidities/manifestations, and the global and historical epidemiological trends for Fabry disease in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK and Japan). It also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of Fabry disease in these markets, segmented by age and sex.